JNM Immediacy Index Increases by 25%

The Journal of Nuclear Medicine (*JNM*)—the flagship publication of SNMMI—has again been ranked among the top medical imaging journals worldwide, according to new data released in late June in the publication *2018 Journal Citation Reports* (Clarivate Analytics). The *Journal Citation Report* publishes an immediacy index as an indicator of the speed with which citations to a specific journal appear in published literature. The 2018 immediacy index for *JNM* is 3.094, a 25% increase over last year and almost double the index of the previous year.

JNM's 2018 impact factor is 7.354, with a 5-year impact factor of 6.738. The journal's citations increased from 27,101 to 27,551, and its article influence score increased from 1.852 to 1.876. *JNM* ranks fifth among the 129 journals included in the medical imaging category—the highest rank among all nuclear medicine journals, with the *European Journal of Nuclear Medicine and Molecular Imaging* close behind.

"The dramatic increase in *JNM*'s immediacy index over the past 2 years demonstrates the journal's influential role in molecular imaging, and we are honored that it is the journal of choice for many distinguished researchers," said editor-in-chief Johannes Czernin, MD. "Among nuclear medicine journals, *JNM* continues to have the highest number of citations, the highest average 5-year impact factor, the highest number of citable articles, and the highest influence score."

The Institute for Scientific Information (ISI), now based in Clarivate Analytics' Scientific and Academic Research Group, measures a journal's impact (or significance) based on the number of article citations compared to the total number of articles published in the previous 2 years. The impact factor—a quantitative measure of the frequency with which an article in a journal is cited—is used to gauge the overall influence of a journal within scientific, professional, and academic communities.

SNMMI New Fellows Honored

At its 2019 Annual Meeting in Anaheim, CA, SNMMI recognized 13 new SNMMI Fellows during a special plenary session on June 24. The SNMMI Fellowship was established in 2016 to recognize distinguished service to the society as well as exceptional achievement in the field of nuclear medicine and molecular imaging. It is among the most prestigious formal recognitions available to longtime SNMMI members.

Satoshi Minoshima, MD, PhD (University of Utah, Salt Lake City) the 2018–2019 SNMMI president, joined the new fellowship ranks. Also recognized were: Carolyn J. Anderson, PhD (University of Pittsburgh Medical Center, PA); Morton D. Blaufox, MD, PhD (Rye, NY); Salvador Borges-Neto, MD (Duke University Medical Center, Durham, NC); Weibo Cai, PhD (University of Wisconsin–Madison); Simindokht Dadparvar, MD (Temple University Hospital, Philadelphia, PA); Jay A. Harolds, MD (Advanced Radiology Services, PC, Grand Rapids, MI); Jason S. Lewis, PhD (Memorial Sloan Kettering Cancer Center, New York, NY); Mark T. Madsen, PhD (University of Iowa, Iowa City); Umar Mahmood, MD, PhD (Massachusetts General Hospital, Charleston); Yasuhito Sasaki, MD, PhD (Shonan Kamakura General Hospital, Japan); Jack J. Slosky, PhD, MBA (currently JJS Consulting, retired from Lantheus Medical

Left to right: SNMMI President Satoshi Minoshima, MD, PhD; Vasken Dilsizian, MD, incoming SNMMI president; and Alan Packard, PhD, SNMMI president-elect; with new SNMMI fellows: Mark Tulchinsky, MD, Jack J. Slosky, PhD, MBA, Yasuhito Sasaki, MD, Umar Mahmood, MD, PhD, Mark T. Madsen, PhD, Jason S. Lewis, PhD, Jay Harolds, MD, Simindokht Dadparvar, MD, Wiebo Cai, PhD, Carolyn Anderson, PhD, and Salvador Borges-Neto, MD.

(Continued on 13N)

Lewis Recognized with 2018 Paul C. Aebersold Award

On June 23 at the SNMMI Annual Meeting in Anaheim, CA, Jason S. Lewis, PhD, was presented with the 2019 Paul C. Aebersold Award for Outstanding Achievement in Basic Nuclear Medicine Science. Lewis is the Emily Tow Jackson Professor and Chair in Oncology, vice chair for research, and chief of the Radiochemistry and Imaging Sciences Service in the Department of Radiology at Memorial Sloan Kettering Cancer Center (MSKCC; New York, NY). "Dr. Lewis has made significant contributions to the field of radiochemistry and nuclear medicine, at both basic and clinical levels," said Sally W. Schwarz, RPh, MS, BCNP, chair of the SNMMI Committee on Awards and a past president of the society. "Jason's accomplishments are enabling a better understanding of the biology of cancer, which is improving treatment of the disease."

Left to right: Carolyn J. Anderson, PhD, Jason S. Lewis, PhD, Umar Mahmood, MD, PhD, and Satoshi Minoshima, MD, PhD

Lewis's research interests focus on radiotracers and radiochemistry. In his lab at MSKCC, faculty and trainees are developing radiopharmaceuticals for targeted diagnosis and treatment of cancer. "I am researching new ways to use PET imaging to diagnose cancer as well as developing new radioimmunotherapies for treating this disease," said Lewis. "By combining small biomolecule–based targeting agents with positron-emitting or therapeutic radioisotopes, we can both interrogate the molecular profiles of cancer using noninvasive nuclear imaging and treat tumors specifically with endoradiotherapy. Our research program is a molecular imaging–based program focused on the targeting of nonstandard nuclides, with an emphasis on developing these novel radiopharmaceuticals for clinical translation."

Dr. Lewis received his undergraduate degree in 1992 and an MSc in chemistry the following year from the University of Essex (Colchester, UK) in the laboratory of Jonathan R. Dilworth, DPhil, DSc. In 1966 he earned a doctorate in biochemistry from the University of Kent (Canterbury, UK), where his mentor was Philip J. Blower, DPhil. His postdoctoral work was with Carolyn J. Anderson, PhD, and Michael J. Welch, PhD, at the Washington University School of Medicine (St. Louis, MO). Lewis became an assistant professor at Washington University's Mallinckrodt Institute of Radiology from 2003 to 2008. In 2008 he joined MSKCC, where today, in addition to his other appointments, he is the director of the Radiochemistry and Molecular Imaging Probe Core Facility and of the Center for Molecular Imaging & Nanotechnology. He is also a professor at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences and at Weill-Cornell Medical College (New York, NY).

Dr. Lewis serves on grant review panels for the National Institutes of Health/National Cancer Institute and on a number of editorial boards. He was president of the World Molecular Imaging Society (2014–2015). He received the SNMMI Berson–Yalow Award (2013), a Distinguished Investigator Award from the Academy of Radiology Research (2014), and was the 2017 SNMMI Michael J. Welch Award winner. He is an associate editor for *The Journal of Nuclear Medicine* and has published more than 300 papers, books, book chapters, and reviews on cancer imaging and radiochemistry.

The Aebersold Award, first presented in 1973, is named for Paul C. Aebersold—a pioneer in the biologic and medical application of radioactive materials and the first director of the Atomic Energy Commission's Division of Isotope Development. In accepting the award, Lewis said, "I am truly honored to receive this honor, although it is important for me to accept it on behalf of all the amazing students, postdocs, and lab members who have worked so hard on all of our projects."

(Continued from 7N)

Imaging, Milton Mills, NH); and Mark Tulchinsky, MD (Penn State Health, Milton S. Hershey Medical Center, Hershey, PA).

Selection of SNMMI fellows is based on documented excellence in volunteer service to the society and at least 1 of 3 additional areas: excellence in scientific discovery and innovation, educational efforts in nuclear medicine and molecular imaging, or clinical practice of nuclear medicine and molecular imaging. SNMMI fellowship is recognized with the designation FSNMMI.